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Reseptorityrosiinikinaasit (RTK) ovat kasvutekijäreseptoreita, jotka välittävät solujen kasvua, 
erilaistumista ja selviytymistä. RTK:en yli-ilmentyminen ja mutaatiot ovatkin tavallista erilaisissa 
sairauksissa, kuten syövässä. Syöpien hoidossa tyrosiinikinaasi-inhibiittorien (TKI) käyttö aikuislla 
on vakiinnuttanut asemansa, mutta lääkkeitä käytetään myös lapsilla ilman hyväksyttyä käyttöaihetta 
(off-label). TKI:en vaikutuksesta kehittyvään elimistöön on kuitenkin edelleen puutteellisesti tietoa, 
mikä rajoittaa käyttöä pediatrisissa syövissä. Tästä huolimatta ErbB RTK-perheeseen kohdistuvien 
TKI:en käytöstä on meneillään useita aikaisen vaiheen kliinisiä kokeita leukemiaan, aivokasvaimiin 
ja osteosarkoomiin pediatrisissa potilaissa, vaikka tietoa näiden vaikutuksista lasten 
neuromuskulaariseen kehitykseen ei ole. Yleisiä haittavaikutuksia aikuisilla ovat lihaskrampit ja tuki- 
ja liikuntaelimistön kivut, erityisesti ErbB4-inhiboivilla laajakirjoisilla TKI:lla. Tämän tutkimuksen 
tarkoitus oli selvittää ErbB-perheeseen kohdistuvien TKI:en vaikutuksia seeprakalan (Danio rerio) 
alkioihin lisätiedon saamiseksi vaikutuksista kehittyvään elimistöön. Seeprakala on yleistymässä 
oleva malli pediatrisessa tutkimuksessa ja in vivo malli lääkkeiden tehokkuudessa ja toksikologiassa.  
Osuudessani tutkimusta villityypin alkiot altistettiin ErbB-perheen TKI:lle. Tämän jälkeen 48 tunnin 
ikäisten alkioiden uintikykyä arvioitiin kosketus-vaste-kokeella, jotka kuvattiin videokameralla. 
Seuraavaksi tarkemmin ErbB4-inhiboimisen vaikutusta uintikykyyn arvioitiin kosketus-vaste-
kokeella erbb4a knockout (CRISPR/Cas9) alkioilla kuten edellä. Lisäksi tutkimuksessa TKI:en 
vaikutuksia arvioitiin Western blottingilla, RT-PCR:lla ja immunofluoresenssi-tutkimuksilla. 
Tutkimuksen tuloksista selvisi, että ErbB4-inhiboiminen häiritsee neuromuskulaarista kehitystä 
seeprakalojen alkioissa. Tuloksista huomattiin laajakirjoisten ErbB-TKI:n ja ErbB4:n estämisen 
vähentävän seeprakalojen alkioiden motiliteettia, luurankolihasten lihassäikeiden halkaisijaa, lihas-
spesifien geenien ilmentymistä ja motoneuronien pituutta. Fenotyyppi ja motiliteetin häiriöt 
korjaantuivat ErbB4:n palauttamisella alkioihin. ErbB4:n tiedetään esiintyvän ihmisilläkin erityisesti 
luurankolihaksissa. Tutkimus korostaa potentiaalisten sivuvaikutusten selvittämisen tarvetta myös 
pediatrisissa potilaissa, jotta TKI:ta voitaisiin käyttää tässäkin potilasryhmässä mahdollisimman 
turvallisesti. 
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ErbB4 tyrosine kinase inhibition impairs 
neuromuscular development in zebrafish 
embryos
ABSTRACT Tyrosine kinase inhibitors are widely used in the clinic, but limited information is 
available about their toxicity in developing organisms. Here, we tested the effect of tyrosine 
kinase inhibitors targeting the ErbB receptors for their effects on developing zebrafish (Danio 
rerio) embryos. Embryos treated with wide-spectrum pan-ErbB inhibitors or erbb4a-targeting 
antisense oligonucleotides demonstrated reduced locomotion, reduced diameter of skeletal 
muscle fibers, and reduced expression of muscle-specific genes, as well as reduced motoneuron 
length. The phenotypes in the skeletal muscle, as well as the defect in motility, were rescued both 
by microinjection of human ERBB4 mRNA and by transposon-mediated muscle-specific ERBB4 
overexpression. The role of ErbB4 in regulating motility was further controlled by targeted muta-
tion of the endogenous erbb4a locus in the zebrafish genome by CRISPR/Cas9. These observa-
tions demonstrate a potential for the ErbB tyrosine kinase inhibitors to induce neuromuscular 
toxicity in a developing organism via a mechanism involving inhibition of ErbB4 function.
INTRODUCTION
Despite the approval of a number of molecularly targeted therapies 
for treating several different cancer types, only a few protocols have 
been clinically tested with pediatric patients. Drugs approved for 
treatment of malignancies in adults are still often used off-label for 
pediatric patients (Zwaan et al., 2010). Clinical pharmacology of 
children, however, differs significantly from that of adults (Kearns 
et al., 2003), and the developing organs may be expected to be 
more vulnerable to toxicity than their mature adult counterparts, with 
a higher percentage of slowly dividing or quiescent cells. In particular, 
this is of potential concern in the case of inhibitors of growth-signal-
ing molecules, such as the receptor tyrosine kinases (RTK).
ErbB receptors are a subfamily of RTKs composed of four mem-
bers: epidermal growth factor receptor (EGFR, ErbB1, HER1), ErbB2 
(HER2), ErbB3 (HER3), and ErbB4 (HER4). ErbB1 and ErbB2 have 
been successfully targeted in different cancer types, such as breast, 
lung, colorectal, gastric, and head and neck, by both therapeutic 
antibodies and tyrosine kinase inhibitors (TKI; Arteaga and 
Engelman, 2014). The recently developed wide-spectrum ErbB 
TKIs, including afatinib, neratinib, canertinib, and dacomitinib, sup-
press the catalytic activity of EGFR and ErbB2 as well as ErbB4, while 
they do not directly target the naturally nearly kinase-inactive ErbB3 
(Schwartz et al., 2014).
During development, the ErbB receptors activate central signal-
ing pathways that regulate vertebrate organogenesis (Holbro and 
Hynes, 2004). A typical mammalian genome includes four erbb 
genes, erbb1, erbb2, erbb3, and erbb4 (Stein and Staros, 2000). In 
the zebrafish (Danio rerio) genome, however, the genes encoding 
EGFR, ErbB3, and ErbB4 have been suggested to have undergone 
another round of duplication, producing erbb1a and erbb1b, 
erbb3a and erbb3b, and erbb4a and erbb4b, while there is only a 
single erbb2 gene (Reischauer et al., 2009).
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One approach to preclinically addressing the toxicity of RTK TKIs 
is analyzing experimental models of growing organisms. Zebrafish 
embryos and larvae are an increasingly used model both for pediat-
ric research (Veldman and Lin, 2008; Lohi et al., 2013) and for in vivo 
testing of drug efficacy and toxicology (MacRae and Peterson, 
2015). Here, we tested several ErbB-targeting TKIs for toxicity in 
zebrafish embryos. Our findings indicate that wide-spectrum pan-
ErbB TKIs, but not EGFR-specific TKIs (nor TKIs with dual specificity 
for EGFR and ErbB2), affected the mobility of the embryos. Valida-
tion experiments with erbb4a-targeting antisense oligonucleotides 
and an erbb4a mutant fish line suggested a critical role for ErbB4 in 
mediating the effects. Mechanistic experiments further indicated 
that the defect in motility was associated with structural defects in 
the developing truncal muscle fibers, changed muscle-specific gene 
expression, and reduced motoneuron length.
RESULTS
Pan-ErbB kinase inhibitors suppress motility of zebrafish 
embryos
To address the effects of ErbB inhibition on developing tissues, 8–h 
past fertilization (hpf) zebrafish embryos were treated for 48 h with 
10 μM of nine different ErbB TKIs. While there were no statistically 
significant differences in the survival of the embryos, some of the 
TKIs were observed to inhibit their movement. To quantitatively an-
alyze the role of ErbB TKIs in regulating motility, touch–response 
assays were carried out (Granato et al., 1996), and the movement of 
the embryos was videorecorded (an example of the procedure is 
shown in Supplemental Movie S1). The swim tracks for individual 
embryos are visualized in Figure 1A and Supplemental Figure S1. 
Inhibitors, such as erlotinib and gefitinib, expected to inhibit EGFR 
alone, did not affect either the length of the swim bursts (Figure 1B) 
or the average speed during the bursts (Figure 1C). A moderate and 
not statistically significant effect was observed with the dual-specific 
EGFR/ErbB2 inhibitor lapatinib (Figure 1, B and C). However, the ir-
reversible pan-ErbB inhibitors afatinib, neratinib, canertinib, and 
dacomitinib, capable of suppressing the activity of EGFR, ErbB2, 
and ErbB4, indicated some reduction in motility, and a statistically 
significant effect was observed for canertinib (Figure 1). While our 
analysis was not sufficiently powered to detect relatively small ef-
fects, these findings suggested that inhibition of the ErbB4 kinase 
was associated with the reduced motility of the embryos. Indeed, 
the TKI AG 1478 shown to block the activity of EGFR as well ErbB4 
(Levitzki and Gazit, 1995; Egeblad et al., 2001) blocked motility in a 
statistically significant manner (Figure 1).
erbb4a is the predominant erbb4 gene expressed during 
zebrafish organogenesis
To address the relative expression of the two erbb4 genes in ze-
brafish, whole embryos were lysed and subjected to real-time re-
verse transcription-PCR (RT-PCR) analysis at different time points 
after fertilization. While both loci were expressed during early de-
velopment, there was a switch of the predominant transcript at 
24 hpf (Supplemental Figure S2A). Expression of erbb4b peaked at 
6 hpf, the earliest time point analyzed, and declined thereafter. In 
contrast, erbb4a was expressed at a low level at 6 hpf, reached a 
similar level to erbb4b at 24 hpf, and further increased to clearly 
dominate over erbb4b at 48 hpf (Supplemental Figure S2A). West-
ern blot analysis with anti-ErbB4 E200 against the intracellular do-
main of ErbB4 confirmed the expression of ErbB4 protein, and 
demonstrated significantly increased protein expression from 
48 hpf onward (Supplemental Figure S2B). Whole mount immuno-
fluorescence analysis with the ErbB4 antibody HFR-1 demonstrated 
the strongest ErbB4 expression in the brain and somites of 48-hpf 
embryos (Supplemental Figure S2, C–F).
FIGURE 1: ErbB kinase inhibitors reduce motility of zebrafish embryos. Touch–response assays measuring motility of 
embryos treated from 8 to 48 hpf with the buffer control DMSO or with 10 μM of the indicated ErbB TKIs. (A) The 
colored lines demonstrate videorecorded tracks of swim bursts of individual embryos stimulated to move by a physical 
touch to the tail. (B, C) Quantification of the length of the entire swim burst (B) and the average speed during the burst 
(C) in the touch–response assays. Mean values are indicated above each column. DMSO, n = 18; erlotinib, n = 14; 
gefitinib, n = 11; osimertinib, n = 9; lapatinib, n = 7, afatinib, n = 7; neratinib, n = 6; canertinib, n = 7; dacomitinib, n = 9; 
AG 1478, n = 11. *p < 0.05.
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erbb4a is necessary for motility of zebrafish embryos
As an independent approach to addressing the function of 
erbb4a, morpholino antisense oligonucleotides were injected into 
one- to eight-cell stage embryos. A morpholino-targeting erbb4a 
mRNA reduced the amount of total ErbB4 protein present in ly-
sate of whole embryos by 99% (Figure 2A, lanes 1 and 2), further 
supporting the significance of erbb4a as the major ERBB4 ortho-
log and also validating the functionality of anti-ErbB4 E200 anti-
body in zebrafish.
Validation experiments with AG 1478 confirmed the observa-
tions of the ErbB kinase inhibitor screen. Similarly to treatment with 
AG 1478, the 48-hpf erbb4a morphant embryos moved for shorter 
distances in response to a contact, as compared with respective 
controls. Figure 2B demonstrates the swim bursts of 10 randomly 
selected embryos treated or not with either erbb4-targeting mor-
pholino. Both the burst length (Figure 2C) and the average velocity 
during the movement (Figure 2D) were reduced in embryos with 
reduced ErbB4 signaling. Both ErbB4 protein expression (Figure 2E) 
and the effects on embryonic motility (Figure 2, F–H) were rescued 
by coinjecting the embryos with human ERBB4 mRNA simultane-
ously with the erbb4a-targeting morpholino oligonucleotide, sup-
porting the specificity of the antisense morpholino approach.
Inhibition of erbb4a induces structural defects in developing 
muscle fibers
To address a potential general effect of erbb4a down-regulation on 
development, the head–trunk angle (HTA) was analyzed as a gross 
measure of developmental stage (Kimmel et al., 1995). No signifi-
cant difference (p = 0.99) in HTA between embryos injected with 
control morpholino (average = 152 ± 13°, n = 13) or morpholino 
targeting erbb4a (average = 152 ± 12°, n = 13) was observed. How-
ever, the number of somites was significantly (p < 0.001) reduced in 
48-hpf erbb4a morphants (29.6 ± 0.3 somites/embryo, n = 18) in 
comparison with the embryos treated with control morpholinos 
(31.2 ± 0.2 somites/embryo, n = 17). A similarly significant (p < 
0.001) decrease in the number of somites was observed in AG 
1478–treated embryos (29.0 ± 0.3 somites/embryo, n = 8) in com-
parison with embryos treated with the dimethyl sulfoxide (DMSO) 
buffer alone (30.8 ± 0.3 somites/embryo, n = 9).
To address the role of erbb4a at the level of skeletal muscle fi-
bers, whole-mount 48-hpf embryos were stained with an anti-myo-
sin antibody and imaged by confocal microscopy (Figure 3A). Both 
the AG 1478 treatment and the erbb4a-targeting morpholino re-
sulted in a significantly reduced diameter of muscle fibers (Figure 3, 
A and B), suggesting a role for ErbB4a signaling in maintaining nor-
mal myocyte morphology.
erbb4a knockdown is associated with reduced motoneuron 
length but not with reduced AchR expression in the skeletal 
muscle
Defects in developing muscle could be secondary to impaired in-
nervation. Indeed, ErbB4 signaling has been suggested to regulate 
AchR expression and function in mouse models (Rimer et al., 2004; 
Schmidt et al., 2011). However, knockdown of erbb4a did not result 
in significant changes in AchR expression in 48-hpf zebrafish em-
bryos when measured either by real-time RT-PCR analysis of AchR 
subunits α1 (chrna1), β1 (chrnb1), and δ (chrnd) (p = 0.08, 0.25, and 
0.86, respectively; n = 10) or by AchR staining with fluorescent α-
bungarotoxin (p = 0.91 for the area covered by fluorescence signal; 
n = 6). In contrast, confocal immunofluorescence analyses of 
motoneurons by anti–synaptotagmin-2 (znp-1) antibody demon-
strated that the motoneuronal axons of erbb4a morphants were 
FIGURE 2: erbb4a is necessary for normal motility of zebrafish embryos. (A) Western blot analysis of ErbB4 expression 
(anti-ErbB4 E200) in 48-hpf embryos injected at the one- to eight-cell stage with erbb4a-targeting or control morpholino 
(lanes 1 and 2). β-tubulin (antibody E7) expression was analyzed from the same lysates to control loading. (B) Touch–
response assays measuring motility of 48-hpf morphants and embryos treated with AG 1478 or untreated. The colored 
lines demonstrate videorecorded tracks of swim bursts of 10 randomly selected embryos stimulated to move by a 
physical touch to the tail. (C, D) Quantification of the length of the swim burst (C) and the average speed during the 
burst (D) in the touch–response assays. Control morpholino, n = 32; erbb4a morpholino, n = 17; DMSO, n = 17; AG 
1478, n = 18. (E) Western blot analysis of ErbB4 expression (anti-ErbB4 E200) in 48-hpf embryos coinjected at the one- 
to eight-cell stage with erbb4a targeting or control morpholino together with in vitro transcribed mRNA encoding EGFP 
or a fusion protein of ErbB4 and EGFP (ERBB4-EGFP). β-tubulin (clone E7) expression was analyzed from the same 
lysates to control loading. (F) Ten randomly selected swim tracks of 48-hpf morphants subjected to touch–response 
assays. (G, H) Quantification of the length of the swim burst (G) and the average speed during the burst (H) in the 
touch–response assays. Control morpholino + EGFP, n = 27; erbb4a morpholino + EGFP, n = 18; erbb4a morpholino + 
ERBB4-EGFP, n = 12.
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shorter than in control morpholino-injected embryos (Figure 3, C 
and D). Similar findings were observed with ErbB kinase inhibitor 
AG 1478–treated embryos (Figure 3, C and D).
Inhibition of ErbB4a alters expression of several muscle-cell 
specific genes
To characterize erbb4a-dependent signaling in the muscle fibers at 
the molecular level, expression of the muscle-specific myosin genes 
cmcl2, myhc4, smyhc1, and tpm1 was analyzed from total lysates of 
48-hpf embryos by real-time RT-PCR. Significantly reduced expres-
sion of smyhc1 and tpm1 was observed after erbb4a morpholino 
injection (Figure 4A) and AG 1478 treatment (Figure 4B). The 
erbb4a-targeting morpholino also significantly reduced the expres-
sion of cmcl2 (Figure 4A).
Western blot analyses indicated that the steady-state expression 
levels of myosin proteins recognized by antibodies raised against 
chicken tropomyosin or chicken fast-type myosin light chain were 
clearly reduced in response to either erbb4a-targeting morpholino 
or AG 1478 (Figure 4C). In contrast, the myosin species recognized 
by antibodies raised against chicken slow-type myosin heavy chain 
remained unchanged after both genetic and chemical down-regula-
tion of ErbB4 function (Figure 4C).
To elucidate the temporal requirement of ErbB activity, AG 1478 
was added to the embryos at 8, 24, or 48 hpf and washed away at 
24, 48, or 72 hpf. The effect on muscular tissue was assessed by 
Western blot analysis of tropomyosin expression at the 72-hpf time 
point for all treatment periods. A robust decrease in tropomyosin 
level was already detected when AG 1478 was administered at 8 hpf 
regardless of the washout time point at 24, 48, or 72 hpf (Figure 4D, 
lanes 2–4 vs. lane 1). An attenuated, but still clear, response was also 
observed at the later treatment period from 24 or 48 hpf to 72 hpf 
(Figure 4D, lane 5 or 6 vs. lane 1).
Rescue of reduced motility of erbb4a morphants by 
muscle-specific ERBB4 expression
To more directly address whether the reduced motility of erbb4a-
deficient embryos was caused by a defect of developing myocytes, 
a construct to overexpress human ERBB4 under the muscle-specific 
acta1 promoter (Jacoby et al., 2009) was cloned, as described in 
Materials and Methods. This construct, encoding both ErbB4 and 
EGFP, or a control construct encoding EGFP alone, was coinjected 
into the embryos with the erbb4a-targeting or control morpholino. 
Interestingly, the mosaic muscle cell–specific expression of ErbB4 in 
the 48-hpf G0 embryos was sufficient to at least partially rescue the 
reduction in the tropomyosin expression (Figure 5A) and the 
reduction of muscle fiber diameter (Figure 5, B and D), as well as the 
shortening of motoneuron axons (Figure 5, C and E). Moreover, the 
expression of the ErbB4 construct with the muscle-specific promoter 
FIGURE 3: Effect of erbb4a knockdown on myocyte and motoneuron morphology. (A) Confocal immunofluorescence 
images of 48-hpf embryos treated from 8 to 48 hpf with 10 μM of the ErbB kinase inhibitor AG 1478 or the DMSO 
buffer alone. Whole-mount embryos were stained with the anti-myosin F59 (red) and the DNA stain 4′,6-diamidine-2-
phenylindole (blue). (B) Quantification of the thickness of individual F59-positive myocytes from confocal 
immunofluorescence images. The number of embryos analyzed was as follows: control morpholino, n = 14; erbb4a 
morpholino, n = 15; DMSO, n = 16; AG 1478, n = 15. Ten myocytes was analyzed from each embryo. (C) Confocal 
immunofluorescence images of 48-hpf embryos injected at the one- to eight-cell stage with erbb4a-targeting or control 
morpholino (top panels) or treated from 8 to 48 hpf with 10 μM of the ErbB kinase inhibitor AG 1478 or the DMSO 
buffer alone (bottom panels). Whole-mount embryos were stained with anti–synaptotagmin-2 (znp-1) to visualize 
motoneurons. Scale bar, 40 μm. (D) Quantification of the length of znp-1-immunoreactive motoneuron axons from 
confocal immunofluorescence images. The numbers of neurons (embryos) analyzed were as follows: control morpholino, 
n = 39 (11); erbb4a morpholino, n = 38 (10); DMSO, n = 33 (11); AG 1478, n = 38 (11).
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was sufficient to partially rescue the compromised motility of the 
erbb4a morphants in the touch–response assays (Figure 5, F–H).
Spontaneous motility is reduced in erbb4a mutant embryos
To control for the reported lack of specificity of the morpholino 
approach (Kok et al., 2014; Rossi et al., 2015), as well as potential 
promiscuity of chemical inhibition, an erbb4a mutant fish line was 
generated using CRISPR/Cas9-mediated targeted mutagenesis. 
We successfully isolated a 22 base pair–deletion allele of erbb4a 
FIGURE 4: erbb4a is necessary for expression of several muscle-specific genes. (A, B) Real-time 
RT-PCR analysis of the expression of muscle-specific genes in 48-hpf embryos injected at the 
one- to eight-cell stage with erbb4a-targeting or control morpholino (A) or treated from 8 to 
48 hpf with 10 μM of the ErbB kinase inhibitor AG 1478 or the DMSO buffer alone (B). Control 
morpholino, n = 10; erbb4a morpholino, n = 10; DMSO, n = 11; AG 1478, n = 12. (C) Western 
blot analyses of the expression of the muscle-specific proteins tropomyosin (clone CH-1), myosin 
light chain (clone F310), and myosin heavy chain (clone F59) in the 48-hpf embryos. (D) Western 
blot analysis of the expression of tropomyosin in embryos treated with 10 μM of AG 1478 for 
the indicated periods of time postfertilization. All other time intervals included incubation with 
DMSO. β-actin (sc-1616) expression was analyzed from the same lysates to control loading.
(erbb4aubs35) (Figure 6A) that causes a 
frame shift and premature stop codon in 
the DNA sequence encoding the extracel-
lular domain of ErbB4a. Based on in silico 
translation, this results in a truncated 
ErbB4a protein lacking transmembrane, ki-
nase, and intracellular domains (Figure 6B). 
Indeed, Western blot analysis of a pool of 
96-hpf mutants using the anti-ErbB4 E200 
recognizing the intracellular domain of 
ErbB4 demonstrated protein expression 
levels reduced to 65% for the heterozy-
gous erbb4a+/ubs35 embryos and to 19% for 
the homozygous erbb4aubs35/ubs35 embryos 
(Figure 6C). The remaining 19% were com-
parable to the relative amount of the 
erbb4b transcript in the homozygous erb-
b4aubs35/ubs35 embryos (16% when com-
pared with the total number of erbb4a + 
erbb4b transcripts in the wild-type em-
bryos by real-time RT-PCR), suggesting 
that the remaining ErbB4-immunoreactive 
band in the mutants derived, not from 
ErbB4a, but from ErbB4b protein.
To measure the effect of the erbb4aubs35 
mutation on motility, an assay recording 
spontaneous motility for a period of 10 min 
was carried out (Supplemental Movie 2). 
Indeed, the embryos homozygous for 
the erbb4aubs35 mutation (erbb4aubs35/ubs35) 
moved for a reduced distance, as well as at 
lower speed, in comparison with heterozy-
gous erbb4a+/ubs35 embryos (Figure 6, D–F).
DISCUSSION
Treatment with pan-ErbB TKIs was observed 
to reduce the motility of developing zebraf-
ish embryos. Several lines of evidence indi-
cate that these effects were mediated, at 
least partially, by ErbB4. Chemical inhibition 
of the ErbB kinase activity, as well as genetic 
targeting of erbb4a, resulted in decreased 
motility of embryos, reduction of the diam-
eter of muscle fibers, and reduced expres-
sion of the myosin genes cmcl2, smyhc1, 
and tpm1. The defects in the motility of the 
embryos were partially rescued by muscle-
specific mosaic expression of human 
ERBB4, implying a requirement for ErbB4 
expressed by the myofibers for the devel-
opment of skeletal muscle. Consistently, the 
motility of embryos with targeted erbb4a 
was reduced both in touch–response as-
says and in assays measuring spontaneous swimming.
Therapeutic TKIs may promote off-target effects by inhibition of 
other structurally homologous kinases. Here, we observed similar 
defects in motility using different ErbB kinase inhibitors, as well as 
by antisense oligonucleotide and mutational approaches targeting 
erbb4a, indicating that the effects on motility were indeed on-target 
and specific for blocking ErbB4 signaling.
To confirm the expression of erbb4a (and erbb4b) in zebrafish in-
dependent of the use of antibodies, we analyzed relevant RNA-seq 
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data sets available in repositories. In the embryonic brain (whole dis-
sected head), the erbb4a expression was relatively high (erbb4a: 2.86 
[range 2.59–3.13] FPKM; erbb4b: 1.53 [1.28–1.78] FPKM; Borck et al., 
2015). In adult muscle, erbb4a was also clearly expressed (erbb4a: 
0.72 [0.58–0.87] FPKM; erbb4b: 0.76 [0.56–0.97] FPKM; Louie et al., 
2017). In FACS-purified spinal cord neurons, erbb4a mRNA was 
expressed at very low level, if at all (erbb4a: 0.016 [0–0.07] FPKM; 
erbb4b: 0.11 [0–0.23] FPKM; Friedmann et al., 2015). Taken together, 
the expression pattern from our immunofluorescence analysis was in 
line with published RNA-seq expression data.
ErbB4 has previously been demonstrated to be expressed in 
human (Plowman et al., 1993; Junttila et al., 2005), mouse (Elenius 
et al., 1997), and rat (Lebrasseur et al., 2003) skeletal muscle tis-
sue. In the rodent myocytes, ErbB4 protein is concentrated in the 
neuromuscular junctions, where it has been suggested to act as a 
postsynaptic neuregulin receptor (Zhu et al., 1995; Trinidad et al., 
2000). The neuromuscular junctions are superficially normal and 
functional in mice lacking both Erbb2 and Erbb4 in the skeletal 
muscle (Escher et al., 2005). However, detailed analysis has dem-
onstrated altered AchR recycling and signal transmission in the 
neuromuscular junctions in the muscles of mice lacking both Erbb2 
and Erbb4 (Schmidt et al., 2011). ErbB4 has also been shown to 
activate AchR transcription in cultured rodent myotubes (Rimer 
et al., 2004). Although our real-time RT-PCR and bungarotoxin la-
beling analyses failed to demonstrate significant quantitative 
changes in AchR expression, it remains to be elucidated whether 
AchR recycling or signaling is affected in the erbb4a-deficient ze-
brafish model.
FIGURE 5: Muscle-specific expression of ERBB4 can rescue neuromuscular phenotypes in erbb4a morphants. Analyses 
of 48-hpf embryos coinjected at the one- to eight-cell stage with erbb4a-targeting or control morpholino together with 
constructs encoding EGFP, or ErbB4 and EGFP (ERBB4/EGFP), under the muscle-specific acta1 promoter. (A) Western 
blot analysis of ErbB4 expression (anti-ErbB4 E200). Tropomyosin (clone CH1) expression was analyzed from the same 
lysates. All the samples were run on the same gels, but some nonrelevant lanes were omitted between samples 2 and 3, 
as indicated by white line. (B) Confocal whole-mount immunofluorescence analysis of GFP-positive mosaic muscle cells. 
GFP = green; anti-ErbB4 (E200) = red. Scale bar, 20 μm. (C) Confocal whole-mount immunofluorescence analysis of 
motoneurons with anti–synaptotagmin-2 (znp-1) antibody. Scale bar, 40 μm. (D) Quantification of the thickness of 
individual GFP-positive myocytes from confocal immunofluorescence images (representative images shown in B). The 
numbers of GFP-expressing myocytes (embryos) analyzed were as follows: control morpholino + EGFP, n = 28 (5); 
erbb4a morpholino + EGFP, n = 65 (5); erbb4a morpholino + ERBB4/EGFP, n = 26 (5). (E) Quantification of the length of 
motoneuron axons from confocal immunofluorescence images (representative images shown in C). The numbers of 
neurons (embryos) analyzed were as follows: control morpholino + EGFP, n = 24 (8); erbb4a morpholino + EGFP, n = 29 
(9); erbb4a morpholino + ERBB4/EGFP, n = 18 (6). (F) Ten randomly selected swim tracks of touch–response assays with 
48-hpf morphants expressing the rescue constructs encoding EGFP, or ErbB4 and EGFP (ERBB4/EGFP), under the 
muscle-specific acta1 promoter. (G, H) Quantification of the length of the swim burst (G) and the average speed during 
the burst (H) in the touch–response assays. Control morpholino + EGFP, n = 32; erbb4a morpholino + EGFP, n = 15; 
erbb4a morpholino + ERBB4/EGFP, n = 20.
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ErbB-targeting TKIs are being tested 
in several early clinical trials for pediatric 
malignancies, such as leukemias, brain 
malignancies, and osteosarcomas (www 
.clinicaltrials.gov). While the extent to which 
ErbB TKIs provoke adverse neuromuscular 
effects in pediatric patients remains to be 
addressed, muscle spasms and musculo-
skeletal pain are among the common side 
effects associated with the ErbB4-targeting 
pan-ErbB inhibitors, such as afatinib, nera-
tinib, and dacomitinib, in adult patients 
(Yang et al., 2012; Chan et al., 2016; Wu 
et al., 2017). Interestingly, inhibitory muta-
tions in the ERBB4 gene have been linked to 
familial and sporadic amyotrophic lateral 
sclerosis (ALS; Takahashi et al., 2013), a dis-
ease characterized by both motoneuron loss 
and muscle atrophy (Al-Chalabi et al., 2012). 
These findings suggest a role of ErbB signal-
ing, and specifically ErbB4, in the regulation 
of neuromuscular function also in humans.
Taken together, our observations indi-
cate that ErbB4 inhibition promotes neuro-
muscular toxicity in developing zebrafish. 
These findings underline the need to char-
acterize the toxicological properties of 
novel molecularly targeted therapeutics 
used for pediatric patients.
MATERIALS AND METHODS
Fish culture
Wild-type zebrafish (D. rerio) were main-
tained according to standard procedures 
(Nüsslein-Volhard and Dahm, 2002) in the 
aquatic facilities of the Laboratory of Animal 
Physiology, University of Turku; Laboratory 
of Aquatic Pathobiology, Åbo Akademi Uni-
versity; and Biozentrum, University of Basel. 
The embryos were cultured at 28.5°C in 
E3 medium (5 mM NaCl, 0.17 mM KCl, 
0.33 mM CaCl2, 0.33 mM MgSO4, 0.01% 
methylene blue). In samples analyzed by 
fluorescence microscopy, pigmentation was 
inhibited by the addition of 0.2 mM phenyl-
thiourea (Sigma) into the E3 medium. Hous-
ing of adult zebrafish and experiments with 
zebrafish embryos were performed accord-
ing to the European Convention for the 
Protection of Vertebrate Animals Used for 
Experimental and Other Scientific Purposes, 
Statutes 1076/85 and 62/2006 of The Ani-
mal Protection Law in Finland, EU Directive 
86/609, and Swiss national guidelines of FIGURE 6: Defective motility in erbb4a mutant embryos. (A) Sanger sequencing data of 
wild-type and mutant erbb4aubs35 alleles. Red and blue lines indicate 5′ and 3′ sequences 
flanking the mutation site, respectively. The black bracket in the wild-type sequence 
indicates the deletion site and sequence missing from the ubs35 mutant allele of erbb4a. 
(B) Schematic presentation of wild-type and mutant ErbB4a proteins. (C) Western blot analysis 
of ErbB4 expression in 96-hpf wild-type and heterozygote (erbb4a+/ubs35) and homozygote 
(erbb4aubs35/ubs35) mutant embryos. Five to six embryos per genotype were pooled for Western 
analysis. (D–F) Spontaneous motility assay. Ninety-six-hpf zebrafish embryos were analyzed for 
spontaneous motility in 24-well plates (1 embryo/well) using a DanioVision instrument. 
(D) Tracks of swimming over a period of 
10 min. (E, F) Quantification of the length of 
the swim tracks (E) and the average speed 
(F). Wild-type erbb4a, n = 13; heterozygote 
erbb4aubs35/+, n = 18; homozygote 
erbb4aubs35/ubs35, n = 13.
216 | I. Paatero et al. Molecular Biology of the Cell
animal experimentation (TSchV) under licenses MMM/465/712-93 
(issued by the Ministry of Agriculture and Forestry, Finland) and 
1014H and 1014G1 (issued by the Veterinäramt-Basel-Stadt).
ErbB tyrosine kinase inhibitors
To block ErbB kinase activity in the embryos, 10 μM of tyrosine ki-
nase inhibitors AG 1478 (Calbiochem), erlotinib, gefitinib, lapatinib, 
afatinib, neratinib, canertinib (all from Santa-Cruz Biotechnologies), 
osimertinib, and dacomitinib (both from Cayman Chemical), diluted 
in DMSO, or DMSO alone was applied in E3 medium at 8 hpf, ex-
cept as indicated for experimentation shown in Figure 4D. The final 
concentration of DMSO was 0.1% of the culture medium.
Morpholino antisense oligonucleotides
To block endogenous expression of erbb4a in zebrafish embryos, a 
morpholino antisense oligonucleotide targeting the translation ini-
tiation site of the erbb4a mRNA (5′-AGAAGGAAGCGAACCGGC-
CACATTT-3′) and a standard control morpholino targeting a mu-
tated splice site of human β-globin mRNA (5′-CCTCTTACCTC 
AGTTACAATTTATA-3′) were purchased from Gene Tools LLC. The 
25 nucleotide–long antisense morpholino sequence contained 15 
mismatches with erbb4b and 12 mismatches with human ERBB4.
DNA constructs and mRNA production
To generate the fusion expression plasmid pcDNA3.1ERBB4EGFP, 
a BglII/NotI fragment of pERBB4-EGFP (Williams et al., 2004) includ-
ing an insert encoding human ErbB4 (nucleotides 99-3974; 
NM_001042599.1) fused to EGFP was blunted and ligated into the 
EcoRV site of pcDNA3.1. A NotI/XbaI fragment of pCS2FA-
transposase (Kwan et al., 2007) encoding the Tol2 transposon was 
inserted into pcDNA3.1 (Invitrogen) to generate pcDNA3.1Tol2. 
RNA was transcribed in vitro from template plasmids pcDNA3.1EGFP 
(kind gift from Chris Cartwright, Stanford University, Stanford, CA), 
pcDNA3.1ERBB4EGFP (human ERBB4), or pcDNA3.1Tol2 using T7 
RNA polymerase and mScript mRNA production system (Epicentre). 
Poly A tails and 5′ cap structures were synthesized using mScript 
mRNA production system (Epicentre).
Plasmids for zebrafish transgenesis were cloned using the Tol2kit 
system (Kwan et al., 2007). The expression constructs pDestTol2A2-
acta1-EGFPpA for expression of the EGFP under the muscle-spe-
cific acta1-promoter was generated in a Gateway LR recombination 
reaction including pDestTol2A2 (Kwan et al., 2007), p5E-acta1 (Ja-
coby et al., 2009), pME-EGFP (Kwan et al., 2007), and p3E-EGFPpA, 
using previously described methods (Kwan et al., 2007). The plas-
mid p3EP2AEGFPpA encoding the self-cleaving peptide P2A from 
porcine teschovirus fused to EGFP was generated from p3E-EGF-
PpA (Kwan et al., 2007) by PCR using the primers 5′-CAGGCTG-
GAGACGTGGAGGAGAACCCTGGACCTGTGAGCAAGGGC-
GAG-GAGCTGTTCAC-3′ and 5′-CTTCAGCAGGCTGAAGTTAGTA 
GCTCCGCTTCCCA-TGGTGGCCACTTTGTACAAGAAAG-3′. The 
P2A peptide allows the expression of two proteins under the same 
promoter, and is functional in zebrafish (Kim et al., 2011). The ex-
pression constructs pDestTol2A2-acta1-ERBB4-P2A-EGFPpA for 
expression of human ErbB4 together with EGFP under the muscle-
specific acta1-promoter was generated in a recombination reaction 
including pDestTol2A2, p5E-acta1, pDONR223-ERBB4 (Addgene 
plasmid 23875; Johannessen et al., 2010), and p3EP2AEGFPpA.
Microinjection of morpholino oligonucleotides, mRNAs, 
and DNA constructs
Embryos at the one- to eight-cell stage were microinjected using 
Femtotip glass capillary needles (Eppendorf) and a Femtojet 
pressure system (Eppendorf) equipped with an Injectman2 micro-
manipulator (Eppendorf) attached to a StereoLumarV.12 stereomi-
croscope (Zeiss). Injection volume was calculated by injecting a 
small droplet into halocarbon oil. The diameter of the droplet was 
measured and the volume calculated.
Volumes of 2–4 nl were used in injections. Morpholinos and in 
vitro transcribed mRNAs were injected into the yolk at final concen-
trations of 7.5 ng/embryo (lowest dose to cause robust erbb4a 
knockdown at 48 hpf) and 500 pg/embryo, respectively. DNA con-
structs were injected into the yolk at a final concentration of 125 pg/
embryo together with 120 pg/embryo of in vitro transcribed Tol2 
transposon mRNA.
CRISPR/Cas9-mediated targeting of endogenous 
erbb4a locus
The guide RNA specific for the erbb4a locus was designed using 
ChopChop online software (Montague et al., 2014; Labun et al., 2016; 
(http://chopchop.cbu.uib.no/). The preparation of single-guide RNA 
(sgRNA) and its injection into one- to four-cell stage embryos were 
performed as previously described (Gagnon et al., 2014). In brief, an 
erbb4a-targeting DNA oligonucleotiude (5´-TTCTAATACGACTC-
ACTATAGAAGCAGAGCTGGCTGTTGTGTTTTAGAGCTAGA-3´) was 
annealed with the DNA oligonucleotide (5´-AAAAGCA CCGACTC-
GGTGCCACTTTTTCAAGTTGATAACGGACTAGCCTTATTTT-
AACTTGCTATTTCTAGCTCTAAAAC-3´). The annealed oligonucle-
otides were filled in using Phusion DNA polymerase. The gel-purified 
DNA fragment was then used as a substrate for the in vitro RNA tran-
scription reaction with T7 RNA polymerase (MAXIscript T7 Transcrip-
tion Kit; Ambion). The resulting sgRNA was precipitated with ethanol 
and ammonium acetate and dissolved in RNase-free water. Purified 
sgRNA was complexed with recombinant Cas9 protein (Gagnon 
et al., 2014) and injected into one- to four-cell stage embryos of the 
Tu zebrafish strain. The injected embryos were grown into adulthood 
and outcrossed with wild-type fish. The founder fish (G0) were identi-
fied by screening the offspring for the presence of mutations in 
erbb4a locus using PCR amplification and digestion with T7 endonu-
clease or AluI (both from New England Biolabs). A 22 base pair–dele-
tion allele (erbb4aubs35) was successfully isolated and F3 generation 
was used in the experiments. The erbb4a genotyping PCR was car-
ried out as nested PCR with outer primer pair (5´-ACTCTGGTTCATT-
GAAACGTCA-3´; 5´-CAT CATGCATCAGAGTGCCAAG-3´) and inner 
primer pair (5´-ATCAACACATGCTGTATCTGCTCT-3´; 5´-CTTGAT-
AGGAA AGTGCAGCGAG-3´) using Taq DNA polymerase (New 
England Biolabs). To obtain DNA, RNA, and protein samples from the 
same individual embryos to allow first genotyping and then pooling 
samples, a NucleoSpin TriPrep kit (Macherey-Nagel) was used.
Protein extraction and Western blotting
Five to twenty embryos were homogenized using a handheld mo-
torized pellet pestle (Sigma) in lysis buffer (1% Triton X-100, 10 mM 
Tris-HCl, pH 7.4, 1 mM EDTA, 2 mM phenyl methyl sulfonyl fluoride, 
10 μg/ml aprotinin, and 10 μg/ml leupeptin) or directly in sample 
buffer (2% SDS, 10% glycerol, 60 mM Tris-HCl, pH 6.8, 100 mM 
dithiothreitol, and 0.01% bromophenol blue). Homogenates were 
centrifuged for 15 min at 12,000 × g at 4°C. Supernatants were ana-
lyzed by Western blotting, as previously described (Kainulainen 
et al., 2000), using the following primary and secondary antibodies: 
anti-ErbB4 (E200; Abcam), anti–β-tubulin (clone E7), anti–slow mus-
cle myosin heavy chain (clone F59), anti–fast muscle myosin light 
chain (clone F310), anti-tropomyosin (clone CH1), anti–β-actin (sc-
1616; Santa Cruz Biotechnology), horseradish peroxidase (HRP)-
conjugated goat anti-rabbit (sc-2004; Santa Cruz Biotechnology), 
Volume 30 January 15, 2019 ErbB inhibitors in zebrafish | 217 
HRP-conjugated goat anti-mouse (sc-2005; Santa Cruz Biotechnol-
ogy), and HRP-conjugated rabbit anti-goat (sc-2768; Santa Cruz Bio-
technology). Anti–β-tubulin, anti-myosin, anti-tropomyosin, and 
anti–synaptotagmin-2 (znp-1) monoclonal antibodies developed by 
M. Klymkowsky, F. E. Stockdale, J.J.-C. Lin, and B. Trevarrow, re-
spectively, were obtained from the Developmental Studies Hybrid-
oma Bank developed under the auspices of the National Institute of 
Child Health and Human Development and maintained by the De-
partment of Biology, University of Iowa, Iowa City.
RNA extraction and real-time RT-PCR
RNA was extracted from one to four embryos homogenized into Tri-
sure RNA extraction reagent (Bioline Reagents) supplemented with 
10 μg/ml glycogen (Roche), as recommended by the manufacturer. 
cDNA was synthesized using the RevertAid H-Reverse Transcription 
kit (Fermentas). Real-time RT-PCR analyses of diluted (1:5) cDNA sam-
ples were carried out using ABI 7900HT (Applied Biosystems) and the 
following primers and probes: erbb4a, 5′-AAACCGCAACTTGTC-
TTTCC-3′, 5′-CCAGAGGAAGATAGTCAAACTGG-3′, probe #21; 
erbb4b, 5′-ATGTGCATCCCCTGCACT-3′, 5′-CGTCTGAAGGCTG-
GCAGT-3′, probe #43; rpl13a, 5′-GCGGACCGAT TCAATAAGGG-3′, 
5′-GAAAGACGACCGAGGTGAGA-3′, probe #147; cmcl2, 5′-CAGG-
AGCCCAGACCAACA-3′, 5′-AGCAGTT TTCCCCCTCTTG-3′, probe 
#112; myhc4, 5′-CAAGCA GAAG CAGCGTGA-3′, 5′-GGGTAGCA-
CAAAGCCTTCAG-3′, probe #82; smyhc1, 5′-TGCCAAGACCAT-
CAGAAATG-3′, 5′-CACACCAAAGTGAATTCGGATA-3′, probe #52; 
tpm1, 5′-GAACGCCTTGGACAGAGC-3′, 5′-TTCCAACTGAATTA-
GTTCGTCTTCT-3′, probe #30; chrna1, 5′-TGTGTTTTACCTGCCCA-
CAG-3′, 5′-GATCAACTCGACGATCACCA-3′, probe #15; chrnb1, 
5′-CGAGTACTTCATCCGCAAGC-3′, 5′-ACCGTCAGGCTGGTATC-
TGT-3′, probe #103; chrnd, 5′-TCATTGTGTTGAACCTGCATT-3′, 
5′-GGAAGACGCTCCAAAA AGAA-3′, probe #107. All primers were 
obtained from Oligomer (Helsinki, Finland), and probes were Univer-
sal ProbeLibrary probes from Roche Applied Sciences.
Immunofluorescence staining
Forty-eight-hpf embryos were fixed with 4% paraformaldehyde (PFA) in 
phosphate-buffered saline (PBS) overnight at 4°C, or with 100% metha-
nol for 20 min at –20°C. The samples were rehydrated in successive 
5-min incubations in solutions containing 100%, 75%, 50%, 25%, and 
0% methanol in PBST (0.1% Tween-20 in PBS). Nonspecific binding was 
blocked in 5% goat serum (Life Technologies) in PBST for 3 h at 4°C. 
The samples were incubated overnight at 4°C with the primary antibod-
ies anti-myosin heavy chain (F59), anti-ErbB4 (HFR-1; Abcam), or anti–
synaptotagmin-2 (znp-1; Developmental Studies Hybridoma Bank) di-
luted in 5% goat serum. After four washes with PBST, the secondary 
antibodies goat anti-mouse Alexa 488 and goat anti-mouse Alexa 555 
(Life Technologies) in 5% goat serum were applied to embryos for 3 h 
at room temperature. After four washes with PBST, the embryos were 
mounted in 87% glycerol for imaging with an LSM510 META confocal 
microscope (Zeiss) or with a StereoLumar V.12 stereomicroscope (Zeiss).
To stain for acetylcholine receptors (AchR), embryos were fixed 
with 4% PFA for 2 h at room temperature, permeabilized with water 
for 4 h at 4°C, and treated with 1 mg/ml collagenase for 45 min at 
room temperature. After three washes with PBS, nonspecific bind-
ing was blocked with PBDT (PBS, 1% bovine serum albumin, 
1% DMSO, 0.5% Triton X-100) supplemented with 5% goat serum 
for 1 h. To visualize AchRs, Alexa-555 labeled α-bungarotoxin (Life 
Technologies) was added to blocking solution and the incubation 
was continued for 3 h at room temperature. After four washes with 
PBDT, the embryos were mounted in glycerol and imaged with a 
Zeiss LSM 510 confocal microscope.
Image processing and analysis were performed using FIJI soft-
ware. Noise in all confocal images was reduced using a median filter 
(2 × 2), and the contrast and brightness of images were adjusted. 
Bungarotoxin-alexa-555 stainings were quantified using median 2 × 
2 filtering, local thresholding (radius 7), and the particle analysis tool 
in FIJI (particle size > 4).
Touch–response assay and digital video motion analysis
To analyze the motility of the zebrafish embryos, a touch–response 
assay was used (Granato et al., 1996). Dechorionated 48-hpf em-
bryos were placed in E3 medium and allowed to accommodate to 
room temperature. The embryos were gently touched at the tail 
with a plastic inoculation loop, and the subsequent swim burst was 
recorded with a digital video camera. Files were converted into AVI 
format, and image analysis was performed using ImageJ and the 
ParticleTracker plug-in (written by Fabrice Cordelieres, Institute 
Curie, Orsay, France; http://rsb.info.nih.gov/ij/plugins/track/track 
.html). Both the distance of the swim burst as well as the average 
velocity during the burst were recorded. Embryos that did not 
show any response to touch were excluded from further analyses.
Assay measuring spontaneous swimming and digital video 
motion analysis
To analyze the motility of erbb4a mutant embryos in the absence of 
physical touch, a DanioVision (Noldus IT) instrument equipped with 
controlled lighting was utilized. The 96-hpf embryos were assayed 
in 24-well plates (1 embryo/well). The plate was subjected to 5 min 
of light, followed by 5 min of darkness. The movement of the em-
bryos was recorded throughout the experiment. The embryos were 
automatically tracked using Ethovision XT software, and the moved 
distance and velocity were measured. After experimentation, the 
embryos were genotyped as described above.
Statistical analyses
Two sample comparisons were performed using Student’s t test and 
three sample comparisons using analysis of variance (ANOVA) 
followed by Dunnet’s t post hoc test (IBM SPSS Statistics 20 and 
GraphPad Prism version 6.05). To improve the fit of data into the 
normal distribution, the touch response data presented in Figure 6, 
G and H, were subjected to transformation by natural logarithm 
prior to ANOVA and Dunnet’s t post hoc test. Columns in figures 
indicate average + standard error.
Bioinformatic analysis of RNA-seq data
Preexisting RNA-seq data sets were analyzed using Chipster soft-
ware v3.12 (Kallio et al., 2011). In brief, the FASTQ files (SRR5115715, 
SRR1648855, and SRR1616929) were retrieved from Sequence 
Read Archive (www.ncbi.nlm.nih.gov/sra), and the reads were aligned 
against the Ensembl genome assembly of the D. rerio genome 
(Danio_rerio.GRCz10.90) using TopHat2 (Kim et al., 2013). This was 
followed by a reference-based assembly of transcripts using 
Cufflinks (Trapnell et al., 2010). FPKM (fragments per kilobase of 
exon model per million reads mapped) values were used to report 
the expression levels.
ACKNOWLEDGMENTS
We thank Erica Nyman, Maria Tuominen, Minna Santanen, and Nina 
Vuori for excellent technical assistance and Deepankar Chakroborty 
with help in video editing. We acknowledge the Cell Imaging Core, 
the Finnish Functional Genomics Centre, and the Zebrafish Core 
Facility (Turku Centre for Biotechnology, University of Turku and Åbo 
Akademi University).
218 | I. Paatero et al. Molecular Biology of the Cell
REFERENCES
Al-Chalabi A, Jones A, Troakes C, King A, Al-Sarraj S, van den Berg LH (2012). 
The genetics and neuropathology of amyotrophic lateral sclerosis. Acta 
Neuropathol 124, 339–352.
Arteaga CL, Engelman JA (2014). ERBB receptors: from oncogene discovery 
to basic science to mechanism-based cancer therapeutics. Cancer Cell 
25, 282–303.
Borck G, Hög F, Dentici ML, Tan PL, Sowada N, Medeira A, Gueneau L, 
Thiele H, Kousi M, Lepri F, et al. (2015). BRF1 mutations alter RNA 
polymerase III-dependent transcription and cause neurodevelopmental 
anomalies. Genome Res 25, 155–166.
Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, Robert NJ, 
Silovski T, Gokmen E, von Minckwitz G, et al. (2016). Neratinib after 
trastuzumab-based adjuvant therapy in patients with HER2-positive 
breast cancer (ExteNET): a multicentre, randomised, double-blind, 
placebo-controlled, phase 3 trial. Lancet Oncol 17, 367–377.
Egeblad M, Mortensen OH, van Kempen LC, Jäättelä M (2001). BIBX1382BS, 
but not AG1478 or PD153035, inhibits the ErbB kinases at different con-
centrations in intact cells. Biochem Biophys Res Commun 281, 25–31.
Elenius K, Corfas G, Paul S, Choi CJ, Rio C, Plowman GD, Klagsbrun M 
(1997). A novel juxtamembrane domain isoform of HER4/ErbB4. Iso-
form-specific tissue distribution and differential processing in response 
to phorbol ester. J Biol Chem 272, 26761–26768.
Escher P, Lacazette E, Courtet M, Blindenbacher A, Landmann L, Bezakova 
G, Lloyd KC, Mueller U, Brenner HR (2005). Synapses form in skeletal 
muscles lacking neuregulin receptors. Science 308, 1920–1923.
Friedmann D, Hoagland A, Berlin S, Isacoff EY (2015). A spinal opsin 
controls early neural activity and drives a behavioral light response. 
Curr Biol 25, 69–74.
Gagnon JA, Valen E, Thyme SB, Huang P, Akhmetova L, Pauli A, Montague 
TG, Zimmerman S, Richter C, Schier AF (2014). Efficient mutagenesis by 
Cas9 protein-mediated oligonucleotide insertion and large-scale assess-
ment of single-guide RNAs. PLoS One 9, e98186.
Granato M, van Eeden FJ, Schach U, Trowe T, Brand M, Furutani-Seiki M, 
Haffter P, Hammerschmidt M, Heisenberg CP, Jiang YJ, et al. (1996). 
Genes controlling and mediating locomotion behavior of the zebrafish 
embryo and larva. Development 123, 399–413.
Holbro T, Hynes NE (2004). ErbB receptors: directing key signaling networks 
throughout life. Annu Rev Pharmacol Toxicol 44, 195–217.
Jacoby AS, Busch-Nentwich E, Bryson-Richardson RJ, Hall TE, Berger J, Berger 
S, Sonntag C, Sachs C, Geisler R, Stemple DL, et al. (2009). The zebrafish 
dystrophic mutant softy maintains muscle fibre viability despite basement 
membrane rupture and muscle detachment. Development 136, 3367–3376.
Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, 
Emery CM, Stransky N, Cogdill AP, Barretina J, et al. (2010). COT drives 
resistance to RAF inhibition through MAP kinase pathway reactivation. 
Nature 468, 968–972.
Junttila TT, Sundvall M, Lundin M, Lundin J, Tanner M, Härkönen P, Joensuu 
H, Isola J, Elenius K (2005). Cleavable ErbB4 isoform in estrogen recep-
tor-regulated growth of breast cancer cells. Cancer Res 65, 1384–1393.
Kainulainen V, Sundvall M, Määttä J, Santiestevan E, Klagsbrun M, Elenius K 
(2000). A natural ErbB4 isoform that does not activate phosphoinositide 
3-kinase mediates proliferation but not survival or chemotaxis. J Biol 
Chem 275, 8641–8649.
Kallio MA, Tuimala JT, Hupponen T, Klemelä P, Gentile M, Scheinin I, Koski 
M, Käki J, Korpelainen EI (2011). Chipster: user-friendly analysis software 
for microarray and other high-throughput data. BMC Genomics 12, 507.
Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauff-
man RE (2003). Developmental pharmacology—drug disposition, ac-
tion, and therapy in infants and children. N Engl J Med 349, 1157–1167.
Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL (2013). 
TopHat2: accurate alignment of transcriptomes in the presence of inser-
tions, deletions and gene fusions. Genome Biol 14, 0–9.
Kim JH, Lee S-R, Li L-H, Park H-J, Park J-H, Lee KY, Kim M-K, Shin BA, Choi 
S-Y (2011). High cleavage efficiency of a 2A peptide derived from porcine 
teschovirus-1 in human cell lines, zebrafish and mice. PLoS One 6, e18556.
Kimmel C, Ballard W, Kimmel S, Ullmann B, Schilling T (1995). Stages of 
embryonic development of the zebrafish. Dev Dyn 203, 253–310.
Kok FO, Shin M, Ni CW, Gupta A, Grosse AS, van Impel A, Kirchmaier BC, 
Peterson-Maduro J, Kourkoulis G, Male I, et al. (2014). Reverse genetic 
screening reveals poor correlation between morpholino-induced and 
mutant phenotypes in zebrafish. Dev Cell 1–12.
Kwan KM, Fujimoto E, Grabher C, Mangum BD, Hardy ME, Campbell DS, 
Parant JM, Yost HJ, Kanki JP, Chien CB (2007). The Tol2kit: a multisite 
gateway-based construction Kit for Tol2 transposon transgenesis con-
structs. Dev Dyn 236, 3088–3099.
Labun K, Montague TG, Gagnon JA, Thyme SB, Valen E (2016). CHOP-
CHOP v2: a Web tool for the next generation of CRISPR genome 
engineering. Nucleic Acids Res 44, W272–W276.
Lebrasseur NK, Coté GM, Miller TA, Fielding RA, Sawyer DB (2003). 
Regulation of neuregulin/ErbB signaling by contractile activity in skeletal 
muscle. Am J Physiol Cell Physiol 284, C1149–C1155.
Levitzki A, Gazit A (1995). Tyrosine kinase inhibition: an approach to drug 
development. Science 267, 1782–1788.
Lohi O, Parikka M, Rämet M (2013). The zebrafish as a model for paediatric 
diseases. Acta Paediatr Int J Paediatr 102, 104–110.
Louie KW, Saera-Vila A, Kish PE, Colacino JA, Kahana A (2017). Temporally 
distinct transcriptional regulation of myocyte dedifferentiation and Myo-
fiber growth during muscle regeneration. BMC Genomics 18, 854.
MacRae CA, Peterson RT (2015). Zebrafish as tools for drug discovery. Nat 
Rev Drug Discov 14, 721–731.
Montague TG, Cruz JM, Gagnon JA, Church GM, Valen E (2014). CHOP-
CHOP: a CRISPR/Cas9 and TALEN web tool for genome editing. 
Nucleic Acids Res 42, W401–W407.
Nüsslein-Volhard C, Dahm R (2002). Zebrafish: A Practical Approach, New 
York: Oxford University Press.
Plowman GD, Culouscou JM, Whitney GS, Green JM, Carlton GW, Foy L, 
Neubauer MG, Shoyab M (1993). Ligand-specific activation of HER4/
p180erbB4, a fourth member of the epidermal growth factor receptor 
family. Proc Natl Acad Sci USA 90, 1746–1750.
Reischauer S, Levesque MP, Nüsslein-Volhard C, Sonawane M (2009). Lgl2 
executes its function as a tumor suppressor by regulating ErbB signaling 
in the zebrafish epidermis. PLoS Genet 5, e1000720.
Rimer M, Prieto AL, Weber JL, Colasante C, Ponomareva O, Fromm L, Schwab 
MH, Lai C, Burden SJ (2004). Neuregulin-2 is synthesized by motor neu-
rons and terminal Schwann cells and activates acetylcholine receptor tran-
scription in muscle cells expressing ErbB4. Mol Cell Neurosci 26, 271–281.
Rossi A, Kontarakis Z, Gerri C, Nolte H, Hölper S, Krüger M, Stainier DYR 
(2015). Genetic compensation induced by deleterious mutations but not 
gene knockdowns. Nature 524, 230–233.
Schmidt N, Akaaboune M, Gajendran N, Martinez-Pena y Valenzuela 
I, Wakefield S, Thurnheer R, Brenner HR (2011). Neuregulin/ErbB 
regulate neuromuscular junction development by phosphorylation of 
α-dystrobrevin. J Cell Biol 195, 1171–1184.
Schwartz PA, Kuzmic P, Solowiej J, Bergqvist S, Bolanos B, Almaden C, 
Nagata A, Ryan K, Feng J, Dalvie D, et al. (2014). Covalent EGFR inhibi-
tor analysis reveals importance of reversible interactions to potency and 
mechanisms of drug resistance. Proc Natl Acad Sci USA 111, 173–178.
Stein RA, Staros JV (2000). Evolutionary analysis of the ErbB receptor and 
ligand families. J Mol Evol 50, 397–412.
Takahashi Y, Fukuda Y, Yoshimura J, Toyoda A, Kurppa K, Moritoyo H, Belzil 
VV, Dion PA, Higasa K, Doi K, et al. (2013). ERBB4 mutations that disrupt 
the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 
19. Am J Hum Genet 93, 900–905.
Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, Van Baren MJ, 
Salzberg SL, Wold BJ, Pachter L (2010). Transcript assembly and quanti-
fication by RNA-Seq reveals unannotated transcripts and isoform switch-
ing during cell differentiation. Nat Biotechnol 28, 511–515.
Trinidad JC, Fischbach GD, Cohen JB (2000). The Agrin/MuSK signaling 
pathway is spatially segregated from the neuregulin/ErbB receptor sig-
naling pathway at the neuromuscular junction. J Neurosci 20, 8762–8770.
Veldman MB, Lin S (2008). Zebrafish as a developmental model organism 
for pediatric research. Pediatr Res 64, 470–476.
Williams CC, Allison JG, Vidal GA, Burow ME, Beckman BS, Marrero L, 
Jones FE (2004). The ERBB4/HER4 receptor tyrosine kinase regulates 
gene expression by functioning as a STAT5A nuclear chaperone. J Cell 
Biol 167, 469–478.
Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, 
Rosell R, Corral J, et al. (2017). Dacomitinib versus gefitinib as first-line 
treatment for patients with EGFR-mutation-positive non-small-cell lung 
cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet 
Oncol 18, 1454–1466.
Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho 
CL, Sequist LV, et al. (2012). Afatinib for patients with lung adenocarci-
noma and epidermal growth factor receptor mutations (LUX-Lung 2): a 
phase 2 trial. Lancet Oncol 13, 539–548.
Zhu X, Lai C, Thomas S, Burden SJ (1995). Neuregulin receptors, erbB3 and 
erbB4, are localized at neuromuscular synapses. EMBO J 14, 5842–5848.
Zwaan CM, Kearns P, Caron H, Verschuur A, Riccardi R, Boos J, Doz F, 
Geoerger B, Morland B, Vassal G (2010). The role of the “innovative 
therapies for children with cancer” (ITCC) European consortium. Cancer 
Treat Rev 36, 328–334.
